JP2024506351A5 - - Google Patents
Info
- Publication number
- JP2024506351A5 JP2024506351A5 JP2023548623A JP2023548623A JP2024506351A5 JP 2024506351 A5 JP2024506351 A5 JP 2024506351A5 JP 2023548623 A JP2023548623 A JP 2023548623A JP 2023548623 A JP2023548623 A JP 2023548623A JP 2024506351 A5 JP2024506351 A5 JP 2024506351A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- modified oligonucleotide
- alkyl
- alkenyl
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163148579P | 2021-02-11 | 2021-02-11 | |
| US63/148,579 | 2021-02-11 | ||
| PCT/US2022/016015 WO2022173976A1 (en) | 2021-02-11 | 2022-02-10 | Compounds and methods for reducing pln expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506351A JP2024506351A (ja) | 2024-02-13 |
| JP2024506351A5 true JP2024506351A5 (enExample) | 2025-02-13 |
Family
ID=82837329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023548623A Pending JP2024506351A (ja) | 2021-02-11 | 2022-02-10 | Ｐｌｎの発現を低減するための化合物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240191232A1 (enExample) |
| EP (1) | EP4291651A4 (enExample) |
| JP (1) | JP2024506351A (enExample) |
| KR (1) | KR20230145133A (enExample) |
| CN (1) | CN117597442A (enExample) |
| AU (1) | AU2022219976A1 (enExample) |
| BR (1) | BR112023015160A2 (enExample) |
| CA (1) | CA3210172A1 (enExample) |
| IL (1) | IL304775A (enExample) |
| MX (1) | MX2023009429A (enExample) |
| WO (1) | WO2022173976A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4689119A1 (en) * | 2023-04-05 | 2026-02-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing pln expression |
| AU2024308906A1 (en) | 2023-06-30 | 2026-02-05 | Atrium Therapeutics, Inc. | Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates |
| TW202528539A (zh) * | 2023-09-20 | 2025-07-16 | 日商第一三共股份有限公司 | 抑制受磷蛋白之表現的siRNA |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1126866B1 (en) * | 1998-11-02 | 2007-02-07 | The Regents of The University of California | A mutant phospholamban molecule and its use in the treatment of cardiac disease and heart failure |
| EP1212416A2 (en) * | 1999-08-31 | 2002-06-12 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid based modulators of gene expression |
| US20030050259A1 (en) * | 1999-12-06 | 2003-03-13 | Lawrence Blatt | Method and reagent for the treatment of cardiac disease |
| AU2005323437B2 (en) * | 2004-04-30 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a C5-modified pyrimidine |
| US7491813B2 (en) * | 2005-12-07 | 2009-02-17 | Monsanto Technology Llc | Promoter polynucleotides identified from Zea mays for use in plants |
| US20100298697A1 (en) * | 2009-05-19 | 2010-11-25 | Medtronic, Inc. | Method and devices for improved efficiency of rna delivery to cells |
| US8207138B2 (en) * | 2009-05-19 | 2012-06-26 | Medtronic, Inc. | Methods and devices for improved efficiency of RNA delivery to cells |
| CA2954791C (en) * | 2014-07-14 | 2025-11-18 | The Regents Of The University Of California | CRISPR/CAS TRANSCRIPTIONAL MODULATION |
| EP3585898A1 (en) * | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders |
-
2022
- 2022-02-10 MX MX2023009429A patent/MX2023009429A/es unknown
- 2022-02-10 CN CN202280027124.1A patent/CN117597442A/zh active Pending
- 2022-02-10 AU AU2022219976A patent/AU2022219976A1/en active Pending
- 2022-02-10 WO PCT/US2022/016015 patent/WO2022173976A1/en not_active Ceased
- 2022-02-10 JP JP2023548623A patent/JP2024506351A/ja active Pending
- 2022-02-10 CA CA3210172A patent/CA3210172A1/en active Pending
- 2022-02-10 KR KR1020237030772A patent/KR20230145133A/ko active Pending
- 2022-02-10 BR BR112023015160A patent/BR112023015160A2/pt unknown
- 2022-02-10 US US18/546,054 patent/US20240191232A1/en active Pending
- 2022-02-10 EP EP22753363.5A patent/EP4291651A4/en active Pending
-
2023
- 2023-07-26 IL IL304775A patent/IL304775A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024506351A5 (enExample) | ||
| KR102675026B1 (ko) | 알파-1 항트립신 (AAT) RNAi 작용제, AAT RNAi 작용제를 포함하는 조성물, 및 사용 방법 | |
| JP2022068222A (ja) | Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬 | |
| JPH09507381A (ja) | 血管平滑筋細胞の増殖の阻害 | |
| JP2022523467A5 (enExample) | ||
| JP2023518409A (ja) | Ａｎｇｐｔｌ３発現を阻害する組成物及び方法 | |
| RS64001B1 (sr) | Metode za lečenje infekcije hepatitisom b | |
| TWI881004B (zh) | 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合 | |
| JP2025508677A5 (enExample) | ||
| JP2023514336A5 (enExample) | ||
| CN111712573B (zh) | 针对骨硬化蛋白的适体及其用途 | |
| US9809823B2 (en) | DNA aptamers for promoting remyelination | |
| JP2024508896A5 (enExample) | ||
| JP2022533358A5 (enExample) | ||
| TW202305135A (zh) | 用於抑制己酮醣激酶（khk）之組合物及方法 | |
| JPH09507387A (ja) | 遺伝子発現の制御 | |
| JP2024538859A5 (enExample) | ||
| KR102156324B1 (ko) | 핵산 복합체를 유효성분으로 함유하는 혈관신생관련 질환 치료용 약학 조성물 | |
| WO2022199685A1 (zh) | 具有延长的体内半衰期的核酸分子缀合物 | |
| KR102685034B1 (ko) | 금속 나노 입자-핵산 결합체를 기반으로 하는 유전자 운반체 | |
| JP2023549500A5 (enExample) | ||
| EP4527934A1 (en) | Gene delivery system based on metal nanoparticle-nucleic acid conjugate | |
| WO2024245424A1 (zh) | 一种用于免疫类疾病的双链核苷酸化合物及其应用 | |
| JP2025504474A5 (enExample) | ||
| JP2025513757A5 (enExample) |